Singapore-based biotechnology company S*BIO Pte, a specialist in the development of small-molecule drugs for the treatment of cancer, says it has signed a two-year Master Research Collaboration Agreement with the country's Institute of Molecular Cell Biology (IMCB), which is part of the Agency for Science, Technology and Research (A*STAR). The company said that the research would focus on the development of multiple compounds for the treatment of cancers, and added that it would develop any promising candidates to the clinical assessment stage, in partnership with A*STAR's newly-formed Experimental Therapeutics Center. Further financial details of the collaboration agreement were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze